Sodium thiosulfate: New hope for the treatment of calciphylaxis

Seminars in Dialysis

Volumn 23, Issue 3, 2010, Pages 258-262

  Hayden, Melvin R ^a,b   Goldsmith, David J A ^a,b  

^a University of Missouri   (United States)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; SODIUM THIOSULFATE; THIOSULFATE;

ARTICLE; CALCINOSIS; CHRONIC KIDNEY FAILURE; HUMAN; MORBIDITY; SURVIVAL RATE; TREATMENT OUTCOME; CALCIPHYLAXIS; COMPLICATION; KIDNEY FAILURE, CHRONIC; TRENDS;

ANTIOXIDANTS; CALCIPHYLAXIS; HUMANS; KIDNEY FAILURE, CHRONIC; MORBIDITY; SURVIVAL RATE; THIOSULFATES; TREATMENT OUTCOME;

EID: 77955152763     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00738.x     Document Type: Article

References (36)

1. Miller MH, Toops TC. Acute cyanide poisoning: recovery with sodium thiosulfate therapy. J Indiana State Med Assoc 1951, 44:1164.
2. Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol 2008, 40:443-451.
3. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008, 17:629-634.
4. Soni S, Leslie WD. Bone scan findings in metastatic calcification from calciphylaxis. Clin Nucl Med 2008, 33:502-504.
5. Raymond CB, Wazny LD. Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm 2008, 65:1419-1429.
6. Musso CG, Enz P, Vidal F, Gelman R, Di Giuseppe L, Bevione P, Garfi L, Galimberti R, Algranati L. Oral sodium thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J Kidney Dis Transpl 2008, 19:820-821.
7. Tindni A, Gaurav K, Panda M. Non-healing painful ulcers in a patient with chronic kidney disease and role of sodium thiosulfate: a case report. Cases J 2008, 1:178.
8. Kyritsis I, Gombou A, Griveas I, Agroyannis I, Retsa K, Agroyannis B. Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism. Int J Artif Organs 2008, 31:742-744.
9. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008, 17:629-634.
10. Hackett BC, McAleer MA, Sheehan G, Powell FC, O'Donnell BF. Calciphylaxis in a patient with normal renal function: response to treatment with sodium thiosulfate. Clin Exp Dermatol 2009, 34:39-42.
11. Kalisiak M, Courtney M, Lin A, Brassard A. Calcific uremic arteriolopathy (calciphylaxis): successful treatment with sodium thiosulfate in spite of elevated serum phosphate. J Cutan Med Surg 2009, 13(Suppl. 1):S29-S34.
12. Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 2009, 5:539-543.
13. Musso CG, Enz P, Vidal F, Gelman R, Lizarraga A, Giuseppe LD, Kowalczuk A, Garfi L, Galimberti R, Algranati L. Use of sodium thiosulfate in the treatment of calciphylaxis. Saudi J Kidney Dis Transpl 2009, 20:1065-1068.
14. Selye H. Calciphylaxis 1962, Chicago, The University of Chicago Press
15. Rees JK, Coles GA. Calciphylaxis in man. Br Med J 1969, 2:670-672.
16. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985, 23:63-67.
17. Yatzidis H, Agroyannis B. Sodium thiosulfate treatment of soft-tissue calcifications in patients with endstage renal disease. Perit Dial Int 1987, 7:250-252.
18. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004, 43:1104-1108.
19. Meissner M, Bauer R, Beier C, Betz C, Wolter M, Kaufmann R, Gille J. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006, 212:373-376.
20. Eckardt KU, Kasiske BL. Kidney disease: improving global outcomes. Nat Rev Nephrol 2009, 5:650-657.
21. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002, 15:172-186.
22. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species, and therapeutic approaches. Oxid Med Cell Longev 2010, 3(2):109-121.
23. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005, 4:4.
24. Tokashiki K, Ishida A, Kouchi M, Ishihara S, Tomiyama N, Kohagura K, Iseki K, Takishita S. Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient. Clin Nephrol 2006, 66:140-143.
25. Sen U, Vacek TP, Hughes WM, Kumar M, Moshal KS, Tyagi N, Metreveli N, Hayden MR, Tyagi SC. Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology 2008, 82:201-213.
26. Sen U, Basu P, Abe OA, Givvimani S, Tyagi N, Metreveli N, Shah KS, Passmore JC, Tyagi SC. Hydrogen sulfide ameliorates hyperhomocysteinemia associated chronic renal failure. Am J Physiol Renal Physiol 2009, 297:F410-F419.
27. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979, 64:1118-1129.
28. Westenfeld R, Schafer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W. Fetuin-A (AHSG) prevents extraosseous calcification induced by uremia and phosphate challenge in mice. Nephrol Dial Transplant 2007, 22:1537-1546.
29. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008, 582:1783-1787.
30. Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahnen-Dechent W, Floege J. Novel insights into uremic vascular calcification: role of matrix Gla protein and Alpha-2-Heremans Schmid Glycoprotein/Fetuin. Blood Purif 2002, 20:473-476.
31. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schike T, Jahnen-Deechent W. The serum protein α2-Heremans-Schmide glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366.
32. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 2003, 59:463-470.
33. Hayden MR. Calciphylaxis and the cardiometabolic syndrome: the emerging role of sodium thiosulfate as a novel treatment option. J Cardiometab Syndr 2008, 3:55-59.
34. Courtney MJ, Pannu N. Calcific uremic arteriolopathy should be treated conservatively. Semin Dial 2010, 23:34-37.
35. Rogers NM, Coates PT. Calcific uremic arteriolopathy-the argument for hyperbaric oxygen and sodium thiosulfate. Semin Dial 2010, 23:38-42.
36. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008, 3:1139-1143.